RXSIGHT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against RxSight, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose significant issues affecting its sales and financial guidance during the specified class period [2][3][4]. Summary by Sections Class Action Lawsuit - The lawsuit is on behalf of all individuals and entities who purchased or acquired RxSight securities between November 7, 2024, and July 8, 2025 [2]. - Investors have until September 22, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Allegations Against RxSight - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [3]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales and overall revenue [4]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, attributing the decline to adoption challenges [4]. - Following this announcement, RxSight's stock price fell nearly 38% [4].